# US 2010/0166733 A1 · Mcp-1 splice variants and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166733 A1
- Document ID: US20100166733A1
- Status: Published application
- Kind: A1
- Application number: 12/305,953
- Filed: 2006-06-21
- Published: 2010-07-01
- Earliest claimed: 2006-06-21
- Inventors: Zurit Levin; Amir Toporik; Michal Ayalon-Soffer; Iris Hecht; Merav Beiman; Dani Eshel; Tali Handelsman
- Web page: https://patentgrep.com/patent/US20100166733A1

## CPC

- C07K 14/523: {Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 37/02: Immunomodulators
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition and/or prognosis of various disorders.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

An isolated polynucleotide coding for a fusion protein comprising a splice variant of MCP-1, wherein said splice variant lacks the predicted C terminal alpha helix of the known human MCP-1 (SEQ ID NO:8), further comprising a polynucleotide having a sequence coding for an immunoglobulin moiety that comprises a constant region of an immunoglobulin.

### Claim 37 (depends on 36)

The polynucleotide of claim 36, wherein the splice variant further comprises an exon encoding a methionine at the junction of exon 2 and 3 of the human gene.

### Claim 38 (depends on 37)

The polynucleotide of claim 37, wherein the splice variant has the sequence set forth in SEQ ID NO:1 or a fragment thereof.

### Claim 39 (depends on 36)

The polynucleotide according to claim 36, wherein the immunoglobulin moiety comprises a heavy chain constant region.

### Claim 40 (depends on 39)

The polynucleotide according to claim 39, wherein the immunoglobulin moiety comprises a human heavy chain constant region.

### Claim 41 (depends on 40)

The polynucleotide according to claim 40, wherein the heavy chain constant region is an IgG1 heavy chain constant region.

### Claim 42 (depends on 41)

The polynucleotide according to claim 41, wherein the immunoglobulin moiety is an IgG1 Fc fragment.

### Claim 43 (depends on 36)

The polynucleotide according to claim 36, comprising a nucleic acid having the sequence set forth in SEQ ID NO:14.

### Claim 44 (depends on 36)

The polynucleotide according to claim 36, wherein the fusion protein further comprises at least one point mutation selected from Y51L and R53V or a combination thereof.

### Claim 45 (depends on 44)

The polynucleotide according to claim 44, wherein the fusion protein comprising both point mutations of Y51L and R53V.

### Claim 46 (depends on 36)

The polynucleotide according to claim 36, wherein the polynucleotide encodes a polypeptide wherein said MCP-1 splice variant has a sequence at least about 95% homologous to SEQ ID NO:9 or a fragment thereof.

### Claim 47 (depends on 36)

The polynucleotide according to claim 36, wherein said polynucleotide encodes a polypeptide wherein said MCP-1 splice variant has a sequence as set forth in SEQ ID NO:9.

### Claim 48

An isolated chimeric polypeptide having a first amino acid sequence being at least about 95% homologous to amino acids 1-64 of S71513_P1 (SEQ ID NO:9), an amino acid M, and a second amino acid sequence selected from an immunoglobulin moiety that comprises a constant region of an immunoglobulin and an isolated Fc moiety, wherein said first amino acid sequence, said amino acid M and said second amino acid sequence are contiguous and in a sequential order.

### Claim 49 (depends on 48)

The polypeptide of claim 48, wherein said first amino acid sequence comprises at least one of the following point mutations: Y51L and R53V.

### Claim 50 (depends on 49)

The polypeptide of claim 49, wherein the first amino acid sequence comprises both point mutations.

### Claim 51 (depends on 48)

The polypeptide of claim 48, wherein the first amino acid sequence consists essentially of SEQ ID NO:9.

### Claim 52 (depends on 48)

The polypeptide of claim 48, wherein the immunoglobulin moiety comprises a heavy chain constant region.

### Claim 53 (depends on 52)

The polypeptide of claim 52, wherein the immunoglobulin moiety comprises a human heavy chain constant region.

### Claim 54 (depends on 53)

The polypeptide of claim 53, wherein the heavy chain constant region is an IgG1 heavy chain constant region.

### Claim 55 (depends on 54)

The polypeptide of claim 54, wherein the immunoglobulin moiety is an IgG1 Fc fragment.

### Claim 56 (depends on 55)

The polypeptide of claim 55, having a sequence consisting essentially of SEQ ID NO:15.

### Claim 57

An isolated chimeric polypeptide having a first amino acid sequence being at least about 95% homologous to amino acids 1-41 of mature MCP-1 variant (SEQ ID NO:35), an amino acid M, and a second amino acid selected from an immunoglobulin moiety that comprises a constant region of an immunoglobulin and an isolated Fc moiety, wherein said first amino acid sequence, said amino acid M and said second amino acid sequence are contiguous and in a sequential order, wherein optionally said first amino acid sequence comprises at least one of the following mutations: Y28L and R30V.

### Claim 58

An isolated polypeptide having an amino acid sequence according to SEQ ID NO:9 with a point mutation selected from Y51L and R53V or both.

### Claim 59 (depends on 36)

An expression vector comprising the polynucleotide sequence according to claim 36.

### Claim 60 (depends on 59)

A host cell comprising the vector according to claim 59.

### Claim 61 (depends on 60)

A process for producing a polypeptide comprising: (i) culturing the host cell according to claim 60 under conditions suitable to produce the polypeptide encoded by said polynucleotide and; (ii) recovering said polypeptide.

### Claim 62 (depends on 36)

A pharmaceutical composition comprising as an active ingredient a polynucleotide sequence according to claim 36, further comprising a pharmaceutically acceptable diluent or carrier.

### Claim 63 (depends on 59)

A pharmaceutical composition comprising as an active ingredient an expression vector according to claim 59, further comprising a pharmaceutically acceptable diluent or carrier.

### Claim 64 (depends on 60)

A pharmaceutical composition comprising as an active ingredient a host cell according to claim 60, further comprising a pharmaceutically acceptable diluent or carrier.

### Claim 65 (depends on 48)

A pharmaceutical composition comprising as an active ingredient a polypeptide according to claim 48, further comprising a pharmaceutically acceptable diluent or carrier.

### Claim 66 (depends on 48)

A method for preventing, treating or ameliorating an MCP-1 related disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising as an active ingredient a polypeptide according to claim 48, wherein said variant treatable disease is selected from the group consisting of:
a. autoimmune diseases, selected from the group consisting of rheumatoid arthritis, multiple sclerosis, scleroderma, systemic lupus erythematosus and inflammatory bowel disease;
b. vascular disorders, selected from the group consisting of atherosclerosis, restenosis after coronary intervention, intimal hyperplasia, arteriogenesis, ischemia and stroke;
c. acute and chronic inflammatory lung diseases, selected from the group consisting of idiopathic pulmonary fibrosis, acute respiratory distress syndrome, allergic asthma, bronchiolitis obliterans syndrome and chronic obstructive pulmonary disease;
d. renal inflammatory diseases, selected from the group consisting of renal fibrosis and injury, nephritis;
e. disorders involving deregulation of leptin secretion, selected from the group consisting of obesity and cachexia;
f. allograft survival following various types of organ transplantation;
g. acute inflammatory conditions, selected from the group consisting of sepsis and peritonitis;
h. other diseases selected from the group consisting of atopic dermatitis, pleurisy, allergic inflammation, colitis, polymyositis and dermatomyositis, uveitis, hepatic fibrosis, myocarditis, arthritis, focal brain ischemia and ischemia-reperfusion injury, ischemia-induced neovascularization, neuropathic pain, insulin-resistance type 2 diabetes.

### Claim 67 (depends on 62)

A method for preventing, treating or ameliorating an MCP-1 related disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition according to claim 62, wherein said variant treatable disease is selected from the group consisting of:
a. autoimmune diseases, selected from the group consisting of rheumatoid arthritis, multiple sclerosis, scleroderma, systemic lupus erythematosus and inflammatory bowel disease;
b. vascular disorders, selected from the group consisting of atherosclerosis, restenosis after coronary intervention, intimal hyperplasia, arteriogenesis, ischemia and stroke;
c. acute and chronic inflammatory lung diseases, selected from the group consisting of idiopathic pulmonary fibrosis, acute respiratory distress syndrome, allergic asthma, bronchiolitis obliterans syndrome and chronic obstructive pulmonary disease;
d. renal inflammatory diseases, selected from the group consisting of renal fibrosis and injury, nephritis;
e. disorders involving deregulation of leptin secretion, selected from the group consisting of obesity and cachexia;
f. allograft survival following various types of organ transplantation;
g. acute inflammatory conditions, selected from the group consisting of sepsis and peritonitis;
h. other diseases selected from the group consisting of atopic dermatitis, pleurisy, allergic inflammation, colitis, polymyositis and dermatomyositis, uveitis, hepatic fibrosis, myocarditis, arthritis, focal brain ischemia and ischemia-reperfusion injury, ischemia-induced neovascularization, neuropathic pain, insulin-resistance type 2 diabetes.
